167 results about "Cognitive decline" patented technology

The present invention relates to the technical field of medical data processing. Disclosed are an electroencephalogram-based cognitive decline risk assessment method and system. In the present invention, a plurality of electroencephalogram representations in electroencephalogram data of a target group and behavioral data of the target group are used to perform training to obtain a first cognitive decline risk assessment model, a second cognitive decline risk assessment model and a third cognitive decline risk assessment model, wherein the first cognitive decline risk assessment model mainly includes spectral information, information included in the second cognitive decline risk assessment model is mainly connection information of a brain network, and the third cognitive decline risk assessment model mainly includes neural spatio-temporal dynamics information. Thus, doctors can be assisted in performing efficient and accurate cognitive decline risk assessment on subjects to be assessed, and patients can be classified on the basis of the cognitive decline risk types of the patients, thereby helping the doctors to quickly formulate rational diagnosis and treatment strategies and improving the working efficiency and quality.

The invention discloses a brain health monitoring and cerebral infarction early warning method and system for old people. The method comprises the steps that electroencephalogram, electrocardio, blood oxygen and cerebral blood flow velocity multi-mode physiological signal data are collected; adopting a characteristic mode decomposition method to decompose the multi-mode physiological signal data; the method comprises the following steps: introducing a KAN network into an MATE structure, carrying out nonlinear mapping and feature reconstruction, and constructing a KAMATE model; an improved Bayesian optimization algorithm is obtained based on the Bayesian optimization algorithm in combination with a dynamic balance strategy; the improved Bayesian optimization algorithm is combined with the characteristic mode decomposition method to achieve characteristic decomposition of the multi-mode physiological signals, and parameters of the KAMATE model are optimized; dividing the brain health state into four grades according to a prediction result output by the KAMATE model; according to the invention, real-time early warning of abnormal cerebral blood supply, cognitive decline and cerebral infarction high-risk states of the elderly can be realized, intelligent support is provided for health management of the elderly, and the method has important application value.

The invention discloses a cognitive disorder progress trend prediction method based on multi-modal data fusion, which comprises the following steps: firstly, acquiring MR I images, PET images, EEG and scale information which comprises clinical cognitive score data, patient age, intelligence quotient score, gender and education degree, and carrying out standardization processing; a feature extraction network composed of a generator and a discriminator is constructed, the MRI image serves as input, high-quality PET image features are generated through the generator, the generated PET image features and real PET image features are discriminated through the discriminator, and then the generator is optimized; constructing an enhanced multi-modal classification model, and performing deep fusion on the MR I image, the generated PET image features, the EEG signals and the clinical cognitive scores to obtain multi-modal features; and 4, inputting multi-modal features, carrying out time sequence modeling by adopting a Mamba model, and predicting the cognitive decline trend of the patient in a future time period.

A medical system useful in the determination of future disease progression in a subject. More specifically the present invention applies machine learning techniques to aid prediction of disease pathology and clinical outcomes in subjects presenting with symptoms of cognitive decline and to expedite clinical development of novel therapeutics.

Disclosed are compounds, and corresponding methods of treatment, that activate myocyte-specific enhancer factor 2 (MEF2) transcriptional activity that are therefore useful in treating deficits in MEF2C activity found in autism spectrum disorder (ASD), intellectual disability (ID), attention deficit and hyperactivity disorder (ADHD), and in diseases characterized by cognitive decline such as Alzheimer's disease (AD), Lewy body dementia (LED), Frontotemporal dementia (FTD), and other forms of dementia, as well as movement disorders such as Parkinson's disease (PD) and parkinsonism from other causes.

The invention belongs to the field of food, and particularly relates to a nutritional composition containing probiotics and oligosaccharides for improving cognition and application of the nutritional composition. A use of a nutritional composition in the preparation of a food product helpful to ameliorate constipation and helpful to ameliorate cognitive competence decline caused by constipation; wherein the nutritional composition comprises the following components (i) and (ii): (i) a bifidobacterium probiotic, and (ii) a sialylated breast milk oligosaccharide; the bifidobacterium probiotics at least comprise animal bifidobacterium subsp. Lactis, and the sialylated breast milk oligosaccharide at least comprises 6 '-sialylated lactose. According to the present invention, the substance combination of the bifidobacterium probiotics and the sialylated breast milk oligosaccharide can improve the abnormal brain-intestine interaction, such that the constipation can be easily improved, and the cognitive competence reduction caused by the constipation can be easily improved; in addition, the bifidobacterium probiotics and the sialylated breast milk oligosaccharide also have a synergistic interaction effect.

The invention belongs to the field of intelligent interaction equipment, and particularly relates to cognitive decline old people intelligent interaction equipment based on AR glasses, which comprises an AR glasses module, an intelligent interaction equipment module and a cloud server module, and the AR glasses module, the intelligent interaction equipment module and the cloud server module carry out real-time data exchange and synchronization through a wireless communication technology. The cloud server module comprises a user interface, a core processing unit, a family member end collaborative management applet and a nursing management module, the nursing management module comprises a nursing closed-loop management module, and eight modules of health management, cognition activation, emotion activation, diet activation, exercise activation, social activation, barrier-free interaction and nursing closed-loop management are combined. All-around intervention is provided for patients with mild cognitive impairment and Alzheimer's disease, cognitive decline is delayed, and the life quality is improved.

A method of treating cognitive decline and / or memory deficits in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one agent that directly or indirectly increases Ptprd activity and / or decreases Aβ induced inhibition of Ptprd activity in the subject.

To provide a multifunctional sheet puzzle that requires three-dimensional inference in the process of solving the puzzle, encourages fine, delicate movements of the fingers, and can be used as an educational teaching material and as a measure against cognitive decline. [Solution] Sheet puzzle a is a foldable, four-sided sheet puzzle characterized by having 16 small sections c on both the front and back of sheet b, with an image d placed within each small section c, and by making three cuts e on the surface of sheet b, sheet b can be folded in any mountain or valley fold, allowing 8 different puzzle solutions to be generated using all 32 images. Furthermore, in the process of solving the puzzle, AI-generated images evoke various associations, develop the imagination, and contain elements that allow the images themselves to be enjoyed, and by selecting the images used, it is expected that advanced usefulness will be achieved in school education as well.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of IFNAR1 RNA in a cell or an animal, and in certain instances, reducing the amount of IFNAR1 protein in a cell or animal. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including Aicardi-Goutieres Syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.

A composition comprising a naphthoquinone-based compound as an active ingredient and uses thereof are disclosed. The composition is effective for preventing or ameliorating fatigue, cachexia, pain, cognitive decline, and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment. The naphthoquinone-based compounds, dunnione and β-lapachone, reduce the secretion and production of inflammatory cytokines which are increased by the anticancer drug treatment, and prevent fatigue, cachexia, cognitive decline, and hematopoietic stem cell reduction which are side effects associated with anticancer drug treatment.

The application discloses application of T1R3 agonist sucralose in relieving Alzheimer's disease and related cognitive impairment, and aims at brain glucose metabolism disorder and cognitive decline problem, and the application takes sucralose as the only pharmaceutical active ingredient, corrects brain glucose metabolism disorder through targeting brain astrocyte sweet taste receptor T1R3, and then treats and relieves neurodegenerative diseases. The application is proved by animal experiments that cognitive dysfunction of AD model mice can be improved in a full range of molecular mechanisms, cell functions, tissue metabolisms and whole behavior, and a variety of dosage forms and medication strategies can be selected, and the application has good in-vivo safety and clinical transformation potential.

The application belongs to the field of food processing and biomedical technology, and discloses a preparation method of a salty taste enhancing peptide-naringenin compound and application of the compound in improving cognitive decline. The compound is prepared by compounding salty taste enhancing peptides from soft-shelled turtle eggs and naringenin at a ratio of 20-150:1 (w:w). The preparation process comprises the following steps: soft-shelled turtle egg enzymolysis, ultrafiltration, freeze-drying to obtain salty taste enhancing peptides, mixing the salty taste enhancing peptides with a naringenin solution, concentration, and freeze-drying. The compound has good stability, salty taste enhancing and antioxidant activities, can reduce the use of salt and maintain salty taste. The compound can improve cognitive decline and anxiety caused by aging and diabetes, improve autonomous activity, memory and social skills, strengthen physical fitness, protect nerve cells and skeletal muscles, maintain brain tissue health, and can be applied to the preparation of related preparations for improving cognitive decline.

Systems and methods of the present disclosure are directed to neural stimulation via audio and visual stimulations. The combination and / or sequence of audio and visual brain stimulations can adjust, control or otherwise manage the frequency of the neural oscillations to provide beneficial effects to one or more cognitive states or cognitive functions of the brain, while mitigating or preventing adverse consequences on a cognitive state or cognitive function that stems from sleep deprivation. In doing so, the present systems and methods can reduce sleep fragmentation, improve sleep quality, and slow the progression of cognitive decline in a subject with Alzheimer's disease and MCI.

In some embodiments herein, methods, compositions, and uses for countering the effects of aberrant meningeal lymphatic drainage and / or modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease associated with aberrant meningeal lymphatic drainage are described. Modulating lymphatic vessels, or countering the effects of aberrant meningeal lymphatic drainage, in accordance with some embodiments, are used to diagnose, treat, prevent, or ameliorate symptoms of neurodegenerative diseases such as Alzheimer's disease (AD) and dementia. Methods of diagnosing and monitoring the progression of neurological diseases are also provided.

An object of a system according to an embodiment is to propose an appropriate countermeasure when there is a suspicion of cognitive decline or Alzheimer's disease.SOLUTION: A system according to an embodiment includes a generation AI, a conversation analysis unit, a suggestion unit, and a share unit. The generated AI interacts with the user. The conversation analysis unit analyzes the conversation content generated by the generation AI. The suggestion unit suggests a BRAIN AGE: Train Your Brain in Minutes a Day!, a quiz, or an appropriate physical exercise when cognitive decline or Alzheimer's disease is suspected on the basis of a result of the analysis by the conversation analysis unit. The sharing unit aggregates a history of conversation contents as a summary or an analysis result, and shares the history with a specific person.SELECTED DRAWING: Figure 1

The present invention discloses a method and system for constructing a prediction model for postoperative cognitive decline in elderly patients, including: generating a preoperative feature matrix; using a static risk prediction model to evaluate the initial risk probability of POCD; introducing a variational autoencoder to model the preoperative feature matrix, and generating a personalized preoperative cognitive state distribution of the patient by learning the implicit distribution of the preoperative feature matrix, thereby completing the initial construction of a digital twin; dynamically collecting cognitive scale scores, physiological indicators, voice features, and behavioral activity data at different time points after surgery to generate a time series feature matrix; inputting the preoperative feature matrix and the time series feature matrix into a dynamic time series model to update the patient's POCD risk probability and cognitive state distribution; simulating a personalized cognitive recovery trajectory, predicting the time it takes for the patient to return to the baseline state, and outputting the optimal intervention strategy to reduce the risk of POCD. The present invention can fine-tune parameters in real time according to newly added data after surgery, provide rapidly updated prediction results, thereby overcoming the problem that existing models are difficult to update prediction results in real time.

Methods and compositions for preventing or treating cognitive decline associated with dementia and / or mild cognitive impairment and / or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG / heparin binding affinities of ApoE.

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful as muscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

The present application belongs to the technical field of medical health, and specifically relates to a type 2 diabetes cognitive function decline prediction system and method. The present application can timely find the cognitive function decline trend by real-time monitoring and analyzing the cognitive function impairment of type 2 diabetes patients, thereby providing a scientific basis for clinical diagnosis and treatment. Through accurate image processing and data analysis, the present application can effectively predict the safety boundary of cognitive function decline and provide personalized prevention and intervention measures for patients. In addition, the present application can accurately assess the level of cognitive function decline according to the diffusion tensor of cognitive function impairment, thereby providing an important reference for doctors to develop treatment plans, and ultimately helping to improve the quality of life of type 2 diabetes patients and reduce the risk of cognitive impairment.

A system and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in a subject based on speech samples. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitively declining patients to generate an ensemble classifier including a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine learning classifier configured to generate a component output that identifies the sample data as corresponding to a normal patient or a cognitively declining patient. The machine learning classifiers are generated based on a subset of available features. The ensemble module receives the component outputs from all of the component classifiers and generates an ensemble output that identifies the sample data as corresponding to a normal patient or a cognitively declining patient based on the component outputs.

The invention discloses a heteroaromatic compound as well as a preparation method and application thereof. The invention provides a compound as shown in a formula I, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The novel aromatic heterocyclic compound is a selective dopamine D1 / D5 ligand, has good affinity and selectivity to a target spot, and can be used for treating D1 / D5-mediated (or D1 / D5-related) disorders including schizophrenia, cognitive impairment, age-related cognitive decline, dementia, Parkinson's disease and the like.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The invention relates to the technical field of individualized cognition, in particular to an individualized cognitive decline risk prediction method and system based on multi-mode data fusion. According to the method, multi-modal longitudinal evidence-based data is integrated on the basis of a group-level pathology law, a multi-scale causal link map capable of reflecting the complete period of cognitive decline is formed, pathology time axis alignment and individualized feature normalization are achieved, the dynamic pathology process of individual specificity can be captured, and the accuracy of the pathology process is improved. By fitting individual exclusive multi-scale causal parameters and constructing a time sequence cascade digital twinborn body, forward causal simulation can be executed on multiple time scales, a cognitive decline core driving path is directly revealed, and individual risk quantification and intervention targets are generated. Detection of early hidden pathological signals, dynamic modeling of individual heterogeneity and comprehensive analysis of a multi-channel pathological mechanism are achieved, the ultra-early prediction precision of cognitive decline and individualized intervention suitability are remarkably improved, and a full-period prediction system capable of being iteratively optimized continuously is formed.

The system notifies family members and the attending physician of changes in the game performance achieved by the person receiving care via a data terminal, allowing the family and the attending physician to share information about the person receiving care's condition, and also to share this information with care support staff at the facility, thereby facilitating the provision of the best possible care. [Solution] In a monitoring system that supports the monitoring of a person receiving care, the first server device 4 manages the history of scores obtained by an intelligent game application installed on a first data terminal 10-1 etc. operated by a person receiving care at a care facility 100, and works in conjunction with a second data terminal 2-1 etc. operated by a caregiver to dynamically grasp the state of cognitive decline of the person receiving care, and is characterized by a configuration that supports a service that provides thorough monitoring of the person receiving care by creating a program to improve the symptoms of the person receiving care.

The invention discloses a traditional Chinese medicine composition for treating kidney-yang deficiency type cognitive decline. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention is composed of the eucommia ulmoides and the total ginsenoside of ginseng, has a remarkable effect on prevention or treatment of cognitive decline, particularly on the aspect of kidney-yang deficiency type cognitive decline, and has a remarkable effect on prevention or treatment of cognitive decline in comparison with the effect of independently using the eucommia ulmoides or the total ginsenoside of ginseng. It can be clearly seen that the traditional Chinese medicine composition has a synergistic effect on prevention or treatment of cognitive decline when used for drug combination.

The invention provides an early biomarker for cognitive impairment of Parkinson's disease, application of the early biomarker and an intelligent analysis system for Parkinson's disease. The biomarker is a GALC gene. The intelligent analysis system for the early biomarkers of the cognitive impairment of the Parkinson's disease comprises a data integration module and a data analysis module. The data integration module is used for acquiring a gene detection result, an olfactory test score and neuroimaging data of the Parkinson's disease biomarker; and the data analysis module is used for analyzing the influence of gene variation of the Parkinson's disease biomarker on olfactory dysfunction and cognitive decline of the Parkinson's disease patient by adopting a structural equation model SEM based on the multi-modal data set. According to the application, through confluence analysis of multi-modal data, by combining genetics, neuroimaging and clinical evaluation, the rs8005172 site variation of the GALC gene is taken as an early biomarker of cognitive impairment of Parkinson's disease, so that PD patients with high cognitive decline risk can be accurately identified.

The present invention provides a method, apparatus and electronic device for identifying a state of ultra-early cognitive decline. The method for identifying a state of ultra-early cognitive decline includes: obtaining basic information and scanned images of a subject, where the basic information includes gender, age and APOE gene information, and the scanned images include Aβ images and Tau images; obtaining feature data based on the scanned images; and inputting the basic information and the feature data into a pre-trained ultra-early cognitive decline state recognition model to identify whether the subject will develop a state of cognitive decline within a predetermined time period. The method for identifying a state of ultra-early cognitive decline according to the present invention can screen out subjects in a state of ultra-early cognitive decline.

Provide herein are methods of treating human patients with familial Alzheimer's disease that result in delayed in symptom onset and / or slowed cognitive decline by administering a humanized monoclonal anti-amyloid beta (Aβ) antibody.